Financials data is unavailable for this security.
View more
Year on year Beijing Sun-Novo Pharmaceutical Research Co Ltd grew revenues 37.76% from 676.61m to 932.12m while net income improved 18.08% from 156.47m to 184.76m.
| Gross margin | 56.06% |
|---|---|
| Net profit margin | 19.82% |
| Operating margin | 21.47% |
| Return on assets | 11.73% |
|---|---|
| Return on equity | 20.94% |
| Return on investment | 18.65% |
More ▼
Cash flow in CNYView more
In 2023, Beijing Sun-Novo Pharmaceutical Research Co Ltd increased its cash reserves by 13.47%, or 82.00m. The company earned 92.86m from its operations for a Cash Flow Margin of 9.96%. In addition the company generated 77.80m cash from financing while 88.66m was spent on investing.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 9.73 |
|---|---|
| Tangible book value per share | 9.46 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.00 |
|---|---|
| Quick ratio | 1.98 |
| Total debt/total equity | 0.4372 |
|---|---|
| Total debt/total capital | 0.3065 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share fell -61.50% while earnings per share excluding extraordinary items rose 17.83%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
| Div yield(5 year avg) | 0.16% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 8.58% |
| EPS growth(5 years) | 54.90 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 14.90 |
More ▼
